S J Connolly
Overview
Explore the profile of S J Connolly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fox K, Eikelboom J, Anand S, Bhatt D, Bosch J, Connolly S, et al.
Eur Heart J
. 2018 Jun;
40(18):1466-1471.
PMID: 29945212
No abstract available.
2.
Proietti M, Hijazi Z, Andersson U, Connolly S, Eikelboom J, Ezekowitz M, et al.
J Intern Med
. 2017 Oct;
283(3):282-292.
PMID: 29044861
Background: Oral anticoagulation is the mainstay of stroke prevention in atrial fibrillation (AF), but must be balanced against the associated bleeding risk. Several risk scores have been proposed for prediction...
3.
Westenbrink B, Alings M, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, et al.
J Thromb Haemost
. 2015 Feb;
13(5):699-707.
PMID: 25683276
Background: Anemia may predispose to thromboembolic events or bleeding in anticoagulated patients with atrial fibrillation (AF). Objectives: To investigate whether anemia is associated with thromboembolic events and bleeding in patients...
4.
Monz B, Connolly S, Korhonen M, Noack H, Pooley J
Int J Cardiol
. 2013 May;
168(3):2540-7.
PMID: 23664436
Background: Anticoagulation is recommended in patients with atrial fibrillation (AF) to prevent strokes. Vitamin K antagonists, such as warfarin, are associated with numerous practical limitations--frequent anticoagulation monitoring, lifestyle and dietary...
5.
Huber K, Connolly S, Kher A, Christory F, Dan G, Hatala R, et al.
Int J Clin Pract
. 2013 Apr;
67(6):516-26.
PMID: 23557519
Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care...
6.
Eikelboom J, Quinlan D, Connolly S, Hart R, Yusuf S
J Thromb Haemost
. 2012 Feb;
10(5):966-8.
PMID: 22360879
No abstract available.
7.
Liesenfeld K, Lehr T, Dansirikul C, Reilly P, Connolly S, Ezekowitz M, et al.
J Thromb Haemost
. 2011 Oct;
9(11):2168-75.
PMID: 21972820
Background: Dabigatran etexilate (DE) is an orally absorbed prodrug of dabigatran, a thrombin inhibitor that exerts potent anticoagulant and antithrombotic activity. Objectives: To characterize the pharmacokinetics of dabigatran in patients...
8.
Healey J, Birnie D, Lee D, Krahn A, Crystal E, Simpson C, et al.
J Cardiovasc Electrophysiol
. 2010 Jul;
21(12):1344-8.
PMID: 20662988
Background: increasingly, ICD implantation is performed without defibrillation testing (DT). Objectives: To determine the current frequency of DT, the risks associated with DT, and to understand how physicians select patients...
9.
Kim Y, Nieuwlaat R, Connolly S, Schulman S, Meijer K, Raju N, et al.
J Thromb Haemost
. 2009 Oct;
8(1):101-6.
PMID: 19840361
Background: The efficacy and safety of vitamin K antagonists for the prevention of thromboembolism are dependent on the time for which the International Normalized Ratio (INR) is in the therapeutic...
10.